Definitive Contract 75N93018C00040
Award Date
8/9/18
Potential Completion Date
5/14/21
Potential Value
$592K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Creare LLC
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Hanover, NH 03755, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,946 Small Business Innovation Research (SBIR) Phase I contract to Aerophase, Inc., a self-certified small disadvantaged business, for the "Treatment of Tuberculosis with Inhaled Delivery of Clofazimine." The contract is a firm-fixed-price definitive contract with a completion date of July 31, 2016. This contract supports research and development of an...
This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Qrumpharma, Inc., a self-certified small disadvantaged business, for a Small Business Innovation Research (SBIR) Program Phase I project. The objective is to determine the feasibility of a clofazimine inhalation formulation for preclinical development in tuberculosis. The contract is a definitive contract with a firm...
This is a fixed-price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Pulmokine, Inc. for the development of "Aerosolized Delivery of Anti-Tubercular Drugs." The contract has a ceiling value of $224,960.00 and a period of performance ending on January 15, 2016. As an SBIR Phase I contract, this award supports early-stage research and...
This is a Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Metallopharm LLC, a small disadvantaged business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract, valued at $224,868.00, is for the development of a formulation for the oral delivery of the antibiotic Capreomycin. The contract has a firm fixed price pricing type and a total small...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $299,995 firm fixed-price contract to Via Therapeutics, LLC, a small business located in Austin, Texas. The contract is for the development of low-cost, shelf-stable, patient-adaptable clofazimine mini-tablets to treat tuberculosis in pediatric patients. This contract supports Via Therapeutics' pharmaceutical research and development efforts related to...
This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...
Via Therapeutics, LLC has been awarded a firm fixed price definitive contract valued at $3,599,145 by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. This contract is set aside for small businesses and will support Phase I of Via Therapeutics' SBIR program efforts to develop an inhaled delivery method for clofazimine, an important drug for treating tuberculosis. The contract aligns with the agency's solicitation...
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to The Global Alliance For TB Drug Development Inc., a non-profit organization. The $9,851,406.00 cost-no-fee contract is for the development of a novel modulator targeting proteostasis for the treatment of M. tuberculosis, with a completion date of April 30, 2028. The contract was awarded under NIAID's Broad...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $216,444 Small Business Innovation Research (SBIR) Phase I contract to Crosslife Technologies Inc., a self-certified small disadvantaged business, to conduct research and development on diagnostics to enable the detection and elimination of malaria and neglected tropical diseases. The contract was awarded under the NIH/CDC SBIR Contract Solicitation PHS...
Zymeron Corporation has been awarded a $300,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to deliver an orodispersible film formulation of a second line drug for pediatric tuberculosis treatment. The contract is set aside for total small businesses and will be completed by August 31, 2022. Performance will take place in Durham, North Carolina. This award supports the National Institute of Allergy and...